HRP20110750T1 - PIPERIDINSKI AGONISTI GPCR-a - Google Patents
PIPERIDINSKI AGONISTI GPCR-a Download PDFInfo
- Publication number
- HRP20110750T1 HRP20110750T1 HR20110750T HRP20110750T HRP20110750T1 HR P20110750 T1 HRP20110750 T1 HR P20110750T1 HR 20110750 T HR20110750 T HR 20110750T HR P20110750 T HRP20110750 T HR P20110750T HR P20110750 T1 HRP20110750 T1 HR P20110750T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- isopropyl
- piperidin
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 229940125633 GPCR agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 54
- 150000003839 salts Chemical class 0.000 claims abstract 38
- 125000000217 alkyl group Chemical group 0.000 claims abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000002431 hydrogen Chemical group 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- -1 2-hydroxy-1-methylethyl Chemical group 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- TYLIJCARBJAAIB-CQSZACIVSA-N 2-methyl-6-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]pyridine-3-carboxamide Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2N=C(C)C(C(N)=O)=CC=2)=N1 TYLIJCARBJAAIB-CQSZACIVSA-N 0.000 claims 1
- MVWISLIFGSKBLY-UHFFFAOYSA-N 2-methyl-6-[3-[1-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3N=C(C)C(C(N)=O)=CC=3)CC2)=N1 MVWISLIFGSKBLY-UHFFFAOYSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- MAYVNVCSUGWQAB-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-2-methyl-6-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3N=C(C)C(C(=O)NC(CO)CO)=CC=3)CC2)=N1 MAYVNVCSUGWQAB-UHFFFAOYSA-N 0.000 claims 1
- TTXDMAKVFXAPIO-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-2-methyl-6-[3-[1-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3N=C(C)C(C(=O)NC(CO)CO)=CC=3)CC2)=N1 TTXDMAKVFXAPIO-UHFFFAOYSA-N 0.000 claims 1
- YENMOMGLDNMICL-MRXNPFEDSA-N n-(2-hydroxyethyl)-2-methyl-6-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]pyridine-3-carboxamide Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2N=C(C)C(C(=O)NCCO)=CC=2)=N1 YENMOMGLDNMICL-MRXNPFEDSA-N 0.000 claims 1
- LGJOTKRPLZOEGR-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-methyl-6-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound CC(C)C1=NOC(N2CCC(CCCOC=3N=C(C)C(C(=O)NCCO)=CC=3)CC2)=N1 LGJOTKRPLZOEGR-UHFFFAOYSA-N 0.000 claims 1
- IWBLOOLAVUKNCS-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-methyl-6-[3-[1-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound O1C(C(C)C)=NC(N2CCC(CCCOC=3N=C(C)C(C(=O)NCCO)=CC=3)CC2)=N1 IWBLOOLAVUKNCS-UHFFFAOYSA-N 0.000 claims 1
- OUMTTXGEQPZPFH-IAGOWNOFSA-N n-[(2r)-1-hydroxypropan-2-yl]-2-methyl-6-[(3r)-3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]butoxy]pyridine-3-carboxamide Chemical compound N1=C(C)C(C(=O)N[C@@H](CO)C)=CC=C1OCC[C@@H](C)C1CCN(C=2ON=C(N=2)C(C)C)CC1 OUMTTXGEQPZPFH-IAGOWNOFSA-N 0.000 claims 1
- ORDNNLRFXKFVAY-MRXNPFEDSA-N n-[(2r)-1-hydroxypropan-2-yl]-2-methyl-6-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound N1=C(C)C(C(=O)N[C@@H](CO)C)=CC=C1OCCCC1CCN(C=2ON=C(N=2)C(C)C)CC1 ORDNNLRFXKFVAY-MRXNPFEDSA-N 0.000 claims 1
- YPDYMOFRGYIWIA-MRXNPFEDSA-N n-[(2r)-2-hydroxypropyl]-2-methyl-6-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]pyridine-3-carboxamide Chemical compound N1=C(C)C(C(=O)NC[C@H](O)C)=CC=C1OCCCC1CCN(C=2ON=C(N=2)C(C)C)CC1 YPDYMOFRGYIWIA-MRXNPFEDSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700125A GB0700125D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
| GB0708746A GB0708746D0 (en) | 2007-05-08 | 2007-05-08 | GPCR agonists |
| GB0719763A GB0719763D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
| PCT/GB2008/050013 WO2008081207A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110750T1 true HRP20110750T1 (hr) | 2011-11-30 |
Family
ID=39199058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110750T HRP20110750T1 (hr) | 2007-01-04 | 2011-10-14 | PIPERIDINSKI AGONISTI GPCR-a |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100105732A1 (sl) |
| EP (2) | EP2114935B1 (sl) |
| JP (1) | JP2010514831A (sl) |
| AR (1) | AR064735A1 (sl) |
| AT (1) | ATE517103T1 (sl) |
| BR (1) | BRPI0806500A2 (sl) |
| CA (1) | CA2674455A1 (sl) |
| CL (1) | CL2008000018A1 (sl) |
| CY (1) | CY1112474T1 (sl) |
| DK (1) | DK2114935T3 (sl) |
| EA (1) | EA015130B1 (sl) |
| HK (1) | HK1135705A1 (sl) |
| HR (1) | HRP20110750T1 (sl) |
| PE (1) | PE20081659A1 (sl) |
| PL (1) | PL2114935T3 (sl) |
| PT (1) | PT2114935E (sl) |
| RS (1) | RS51943B (sl) |
| SA (1) | SA08280757B1 (sl) |
| SI (1) | SI2114935T1 (sl) |
| TW (1) | TW200835482A (sl) |
| WO (1) | WO2008081207A1 (sl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0516407A (pt) * | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
| CA2613235A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| AR064736A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
| JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
| CN104016970A (zh) | 2007-10-10 | 2014-09-03 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812641D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| WO2010084512A1 (en) * | 2008-12-24 | 2010-07-29 | Cadila Healthcare Limited | Novel oxime derivatives |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| AR077215A1 (es) | 2009-06-24 | 2011-08-10 | Boehringer Ingelheim Int | Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos |
| WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012066077A1 (en) | 2010-11-18 | 2012-05-24 | Prosidion Limited | 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| JP6463631B2 (ja) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Ｇｐｒ−１１９のモジュレータとしての新規化合物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
| CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
| DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
| US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
| FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| AU3784997A (en) * | 1996-08-09 | 1998-03-06 | Eisai Co. Ltd. | Benzopiperidine derivatives |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| AU756244B2 (en) | 1998-09-01 | 2003-01-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous G protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| CN1206220C (zh) * | 2000-11-21 | 2005-06-15 | 三菱化学株式会社 | 生产2－(4－吡啶基)乙硫醇的方法 |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| AU2002331766A1 (en) | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| MXPA03009439A (es) | 2001-09-21 | 2004-02-12 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1. |
| IL160081A0 (en) | 2001-09-21 | 2004-06-20 | Solvay Pharm Bv | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
| EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| WO2003082190A2 (en) | 2002-03-26 | 2003-10-09 | Merck & Co., Inc. | Spirocyclic amides as cannabinoid receptor modulators |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| WO2003087037A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
| CA2481313A1 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| RU2304580C2 (ru) | 2002-07-29 | 2007-08-20 | Ф.Хоффманн-Ля Рош Аг | Новые бензодиоксолы |
| US7091216B2 (en) | 2002-08-02 | 2006-08-15 | Merck & Co., Inc. | Substituted furo[2,3-b]pyridine derivatives |
| AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| US7319110B2 (en) | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
| AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| BR0314872A (pt) | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| PL378244A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1 |
| WO2004060870A1 (en) | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Novel cb 1 receptour inverse agonists |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| CA2514791A1 (en) | 2003-02-13 | 2004-08-26 | Aventis Pharma Deutschland Gmbh | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments |
| MXPA05007516A (es) | 2003-02-13 | 2006-01-27 | Sanofi Aventis Deutschland | Derivados de hexahidropirazino[1,2-a]pirimidina -4, 7-diona sustituidos, metodo para producirlos y su uso como medicamentos. |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| WO2004078261A1 (en) | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
| KR101154830B1 (ko) | 2003-12-24 | 2012-06-18 | 프로시디온 리미티드 | Ｇｐｃｒ 수용체 효능제로서의 헤테로사이클릭 유도체 |
| BRPI0516407A (pt) * | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
| JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Ｇタンパク質結合受容体作動薬 |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| CA2613236A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
| CA2613235A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| AU2007235673A1 (en) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic GPCR agonists |
| UA97817C2 (ru) * | 2006-12-06 | 2012-03-26 | Глаксосмиткляйн Ллк | Гетероциклические производные 4-(метилсульфонил)фенила и их применение |
| AR064736A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
-
2008
- 2008-01-03 AR ARP080100017A patent/AR064735A1/es unknown
- 2008-01-03 CL CL200800018A patent/CL2008000018A1/es unknown
- 2008-01-03 PE PE2008000084A patent/PE20081659A1/es not_active Application Discontinuation
- 2008-01-04 PT PT08702096T patent/PT2114935E/pt unknown
- 2008-01-04 WO PCT/GB2008/050013 patent/WO2008081207A1/en active Application Filing
- 2008-01-04 DK DK08702096.2T patent/DK2114935T3/da active
- 2008-01-04 JP JP2009544450A patent/JP2010514831A/ja active Pending
- 2008-01-04 EP EP08702096A patent/EP2114935B1/en active Active
- 2008-01-04 PL PL08702096T patent/PL2114935T3/pl unknown
- 2008-01-04 RS RS20110448A patent/RS51943B/en unknown
- 2008-01-04 TW TW097100416A patent/TW200835482A/zh unknown
- 2008-01-04 BR BRPI0806500-4A2A patent/BRPI0806500A2/pt not_active IP Right Cessation
- 2008-01-04 EA EA200900880A patent/EA015130B1/ru not_active IP Right Cessation
- 2008-01-04 EP EP11169308A patent/EP2377864A1/en not_active Withdrawn
- 2008-01-04 SI SI200830401T patent/SI2114935T1/sl unknown
- 2008-01-04 US US12/522,023 patent/US20100105732A1/en not_active Abandoned
- 2008-01-04 AT AT08702096T patent/ATE517103T1/de active
- 2008-01-04 CA CA002674455A patent/CA2674455A1/en not_active Abandoned
- 2008-01-05 SA SA8280757A patent/SA08280757B1/ar unknown
-
2010
- 2010-04-16 HK HK10103733.4A patent/HK1135705A1/xx not_active IP Right Cessation
-
2011
- 2011-10-14 HR HR20110750T patent/HRP20110750T1/hr unknown
- 2011-10-17 CY CY20111100985T patent/CY1112474T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2674455A1 (en) | 2008-07-10 |
| EP2114935B1 (en) | 2011-07-20 |
| PL2114935T3 (pl) | 2012-03-30 |
| BRPI0806500A2 (pt) | 2014-04-22 |
| DK2114935T3 (da) | 2011-10-31 |
| EP2377864A1 (en) | 2011-10-19 |
| PT2114935E (pt) | 2011-10-17 |
| PE20081659A1 (es) | 2008-10-24 |
| CY1112474T1 (el) | 2015-12-09 |
| WO2008081207A1 (en) | 2008-07-10 |
| EA015130B1 (ru) | 2011-06-30 |
| SI2114935T1 (sl) | 2011-11-30 |
| EA200900880A1 (ru) | 2010-02-26 |
| HK1135705A1 (en) | 2010-06-11 |
| TW200835482A (en) | 2008-09-01 |
| EP2114935A1 (en) | 2009-11-11 |
| AR064735A1 (es) | 2009-04-22 |
| JP2010514831A (ja) | 2010-05-06 |
| RS51943B (en) | 2012-02-29 |
| ATE517103T1 (de) | 2011-08-15 |
| US20100105732A1 (en) | 2010-04-29 |
| CL2008000018A1 (es) | 2008-08-01 |
| SA08280757B1 (ar) | 2011-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110750T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| HRP20110852T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| HRP20110964T1 (hr) | PIPERIDINSKI AGONISTI GPCR-a | |
| AU2010313068B2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| CN102712624B (zh) | 吲哚化合物及其制药用途 | |
| ES2430223T3 (es) | Derivados de isoxazol-piridina como moduladores de GABA | |
| ES2326182T3 (es) | Derivados de metilendipiperidina. | |
| PE20091901A1 (es) | Activadores de glucoquinasa | |
| PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
| US20070105847A1 (en) | 1,3-Dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos | |
| BG106483A (bg) | Нови спирохетероциклени съединения като инхибитори с обратимо действие на цистеин протеази | |
| PE20060727A1 (es) | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
| PE20060415A1 (es) | Compuestos heteroaril- y fenilsulfamoilo sustituidos | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| HRP20110796T1 (hr) | Postupak dobivanja | |
| PE20081485A1 (es) | Derivados de sulfonamida | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| PE20070495A1 (es) | COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE | |
| PE20120732A1 (es) | Agonistas del receptor de esfingosina-1-fosfato | |
| WO2011106627A1 (en) | Substituted hydroxamic acids and uses thereof | |
| PE20120024A1 (es) | DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN | |
| RU2009117209A (ru) | 2-пиридинкарбоксамидное производное, обладающее gk-активирующим действием |